Access in all areas? A round up of developments in market access and health technology assessment: part 7

In this update, we discuss the implementation progress of the Medicare Drug Price Negotiation Program, with particular focus on the second round of negotiations for 15 additional Part D drugs; explore the role of health technology assessment in US commercial health plan decision-making; and examine significant changes to pharmaceutical pricing systems in Germany, where international reference pricing has been eliminated as part of the Medical Research Act.